Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage. This is an ASCO Meeting Abstract ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...

In a randomized clinical trial, Mass General Brigham researchers found testosterone replacement therapy also improved quality of life for men who had undergone radical prostatectomy ...